Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü

Ercan BAŞTU, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, İnfertilite Bilim Dalı, İstanbul, Türkiye)
Mehmet Fırat MUTLU, (Boş)
Özlem DURAL, (Sağlık Bakanlığı, Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, Perinatoloji Bilim Dalı, İstanbul, Türkiye)
Faruk BUYRU (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, İnfertilite Bilim Dalı, İstanbul, Türkiye)
Endokrinolojide Diyalog Dergisi
3 0
Yıl: 2012 Cilt: 9 Sayı: 4 Sayfa Aralığı: 179 - 185 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü

Öz:
Tekrarlayan gebelik kayıpları (TGK) ve endokrin hastalıklar arasındaki ilişki uzun zamandır bilinmektedir. Embriyonun tutunması ve erken implantasyonunda lokal hormonalar etkin olduğundan, endokrin sebepli gebelik kayıplar genellikle erken gestasyonal dönemde oluşur. TGK ile en sık ilişkilendirilen endokrin bozukluklar arasında tiroid hastalıkları, luteal faz bozuklukları ve polikistik over sendromu sayılabilir. Bu derlemede amacımız, bu hastalıkların patofizyolojisinde yeni gelişmeleri incelerken, gebelik sürecini ve sonucunu nasıl etkilediklerini irdelemektir.
Anahtar Kelime:

Konular: Kadın Hastalıkları ve Doğum

Role of endocrine disorders in recurrent early pregnancy loss

Öz:
Existence of a link between endocrine disorders and recurrent pregnancy loss (RPL) has been well established. Since embryo attachment and early implantation are managed by the local hormonal milieu, endocrine-related pregnancy failures usually occur during early gestation. Endocrine abnormalities, such as thyroid disorders, luteal phase defects and polycystic ovary syndrome, are commonly associated with RPL. In this review we discuss new concepts in the pathophysiology and treatment of these diseases and their effects on pregnancy maintenance and outcome.
Anahtar Kelime:

Konular: Kadın Hastalıkları ve Doğum
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Boklage CE. Survival probability of human conceptions from fertilization to term. Int J Fertil 1990;35(2):75–94.
  • 2. Wilcox AJ, Weinberg CR, O’Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988;319(4):189–194.
  • 3. Edmonds DK, Lindsay KS, Miller JF, Williamson E, Wood PJ. Early embryonic mortality in women. Fertil Steril 1982;38(4):447–453.
  • 4. Rai R, Regan L. Recurrent miscarriage. Lancet 2006;368(9535):601–611.
  • 5. Suzumori N, Sugiura-Ogasawara M. Genetic factors as a cause of miscarriage. Curr Med Chem 2010;17(29):3431– 3437.
  • 6. Alberman E. The epidemiology of repeated abortion. In: Beard RW, Sharp F, eds. Early Pregnancy Loss: Mechanisms and Treatment. New York, NY: Springer-Verlag; 1988:9–17.
  • 7. Fryns JP, Van Buggenhout G. Structural chromosome rearrangements in couples with recurrent fetal wastage. Eur J Obstet Gynecol Reprod Biol 1998;81(2):171–176.
  • 8. Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010;93(4):1234–1243.
  • 9. Proctor JA, Haney AF. Recurrent first trimester pregnancy loss is associated with uterine septum but not with bicornuate uterus. Fertil Steril 2003;80(5):1212–1215.
  • 10. Propst AM, Hill JA III. Anatomic factors associated with recurrent pregnancy loss. Semin Reprod Med 2000;18(4):341–350.
  • 11. Homer HA, Li TC, Cooke ID. The septate uterus: a review of management and reproductive outcome. Fertil Steril 2000;73(1):1–14.
  • 12. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4(2):295–306.
  • 13. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010;115(6):1256–1262.
  • 14. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18(3):404–433.
  • 15. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol 2009;160(6):985–991.
  • 16. Poppe K, Velkeniers B, Glinoer D. Thyroid disease and female reproduction. Clin Endocrinol (Oxf) 2007;66(3):309–321.
  • 17. Glinoer D. Thyroidal and immune adaptation to pregnancy: focus on maternal hypo- and hyperthyroidism. In: Lazarus J, Pirags V, Butz S, eds. The Thyroid and Reproduction. New York, NY: Thieme; 2009:46–58.
  • 18. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87(2):489– 499.
  • 19. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172(4379):603–606.
  • 20. Anjum N, Baker PN, Robinson NJ, Aplin JD. Maternal celiac disease autoantibodies bind directly to syncytiotropho- blast and inhibit placental tissue transglutaminase activity. Reprod Biol Endocrinol 2009;7:16.
  • 21. Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Alvarez- Marfany M, Davies TF. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA 1990;264(11):1422–1425.
  • 22. Bussen S, Steck T. Thyroid autoantibodies in euthyroid nonpregnant women with recurrent spontaneous abortions. Hum Reprod 1995;10(11):2938–2940.
  • 23. Glinoer D, Soto MF, Bourdoux P, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab 1991; 73(2):421–427.
  • 24. Kutteh WH, Yetman DL, Carr AC, Beck LA, Scott RT Jr. Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction. Fertil Steril 1999;71(5):843–848.
  • 25. Pratt D, Novotny M, Kaberlein G, Dudkiewicz A, Gleicher N. Antithyroid antibodies and the association with non-organ-specific antibodies in recurrent pregnancy loss. Am J Obstet Gynecol 1993;168:837–841.
  • 26. Singh A, Dantas ZN, Stone SC, Asch RH. Presence of thyroid antibodies in early reproductive failure: biochemical versus clinical pregnancies. Fertil Steril 1995;63(2):277–281.
  • 27. Esplin MS, Branch DW, Silver R, Stagnaro-Green A. Thyroid autoantibodies are not associated with recurrent pregnancy loss. Am J Obstet Gynecol 1998;179:1583–1586.
  • 28. Rushworth FH, Backos M, Rai R, Chilcott IT, Baxter N, Regan L. Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies. Hum Reprod 2000;15(7):1637–1639.
  • 29. Kaprara A, Krassas GE. Thyroid autoimmunity and miscarriage. Hormones (Athens) 2008;7(4):294–302.
  • 30. Matalon ST, Blank M, Ornoy A, Shoenfeld Y. The association between anti-thyroid antibodies and pregnancy loss. Am J Reprod Immunol 2001;45(2):72–77.
  • 31. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro- Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010;95(9):E44–E48.
  • 32. De Vivo A, Mancuso A, Giacobbe A, et al. Thyroid function in women found to have early pregnancy loss. Thyroid 2010;20(6):633–637.
  • 33. Smyth PP, Wijeyaratne CN, Kaluarachi WN, et al. Sequential studies on thyroid antibodies during pregnancy. Thyroid 2005;15(5):474–477.
  • 34. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12(1):63–68.
  • 35. Bussen S, Steck T, Dietl J. Increased prevalence of thyroid antibodies in euthyroid women with a history of recurrent in vitro fertilization failure. Hum Reprod 2000;15(3):545–548.
  • 36. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006; 91(7):2587–2591.
  • 37. Vaquero E, Lazzarin N, De Carolis C, Valensise H, Moretti C, Ramanini C. Mild thyroid abnormalities and recurrent spontaneous abortion: diagnostic and therapeutical approach. Am J Reprod Immunol 2000;43(4):204–208.
  • 38. Reid SM, Middleton P, Cossich MC, Crowther CA. Interventions for clinical and subclinical hypothyroidism in pregnancy. Cochrane Database Syst Rev 2010;(7):CD007752.
  • 39. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med 2004;351(3):241–249.
  • 40. Glinoer D. Thyroid immunity, thyroid dysfunction, and the risk of miscarriage: a propos article by Vaqueroetal. Mild thyroid abnormalities and recurrent spontaneous abortion: diagnostic and therapeutical approach. Am J Reprod Immunol 2000;43(4):202–203.
  • 41. Glinoer D, Delange F. The potential repercussions of maternal, fetal, and neonatal hypothyroxinemia on the progeny. Thyroid 2000;10(10):871–887.
  • 42. Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990;323(2):91–96.
  • 43. Valbuena D, Jasper M, Remoh J, Pellicer A, Simon C. Ovarian stimulation and endometrial receptivity. Hum Reprod 1999;14(Suppl 2):107–111.
  • 44. Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973;115(6):759–765.
  • 45. Jones GS. The luteal phase defect. Fertil Steril 1976;27(4):351–356.
  • 46. Arredondo F, Noble LS. Endocrinology of recurrent pregnancy loss. Semin Reprod Med 2006;24(1):33–39.
  • 47. Horta JL, Fernandez JG, de Leon BS, Cortes-Gallegos V. Direct evidence of luteal insufficiency in women with habitual abortion. Obstet Gynecol 1977;49(6):705–708.
  • 48. Serle E, Aplin JD, Li TC, et al. Endometrial differentiation in the peri-implantation phase of women with recurrent miscarriage: a morphological and immunohistochemical study. Fertil Steril 1994;62(5):989–996.
  • 49. Li TC, Spuijbroek MD, Tuckerman E, Anstie B, Loxley M, Laird S. Endocrinological and endometrial factors in recurrent miscarriage. BJOG 2000;107(12):1471–1479.
  • 50. Tulppala M, Bjorses UM, Stenman UH, Wahlstrom T , Ylikorkala O. Luteal phase defect in habitual abortion: progesterone in saliva. Fertil Steril 1991;56(1):41–44.
  • 51. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol 1975;122(2):262–263.
  • 52. Duggan MA, Brashert P, Ostor A, et al. The accuracy and interobserver reproducibility of endometrial dating. Pathology 2001;33(3):292–297.
  • 53. Scott RT, Snyder RR, Strickland DM, et al. The effect of interobserver variation in dating endometrial histology on the diagnosis of luteal phase defects. Fertil Steril 1988;50(6):888– 892.
  • 54. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol 1989;96(3):275–280.
  • 55. Scott RT, Snyder RR, Bagnall JW, Reed KD, Adair CF, Hensley SD. Evaluation of the impact of intraobserver variability on endometrial dating and the diagnosis of luteal phase defects. Fertil Steril 1993;60(4):652–657.
  • 56. Gibson M, Badger GJ, Byrn F, Lee KR, Korson R, Trainer TD. Error in histologic dating of secretory endometrium: variance component analysis. Fertil Steril 1991;56(2):242– 247.
  • 57. Smith S, Hosid S, Scott L. Endometrial biopsy dating. Interobserver variation and its impact on clinical practice. J Reprod Med 1995;40(1):1–3.
  • 58. Sherman BM, Korenman SG. Measurement of plasma LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the short luteal phase. J Clin Endocrinol Metab 1974;38(1):89–93.
  • 59. Harrison RF. Human chorionic gonadotrophin (hCG) in the management of recurrent abortion; results of a multi-centre placebo- controlled study. Eur J Obstet Gynecol Reprod Biol 1992;47(3):175–179.
  • 60. Li TC, Tuckerman EM, Laird SM. Endometrial factors in recurrent miscarriage. Hum Reprod Update 2002;8(1):43–52.
  • 61. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008;(2):CD003511.
  • 62. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002;17(11):2858–2864.
  • 63. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Ga ̈rtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150(3): 363–369.
  • 64. Dorman JS, Burke JP, McCarthy BJ, et al. Temporal trends in spontaneous abortion associated with type 1 diabetes. Diabetes Res Clin Pract 1999;43(1):41–47.
  • 65. Mills JL, Simpson JL, Driscoll SG, et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med 1988;319(25):1617–1623.
  • 66. Cocksedge KA, Li TC, Saravelos SH, Metwally M. A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage. Reprod Biomed Online 2008;17(1): 151–160.
  • 67. Craig LB, Ke RW, Kutteh WH. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002;78(3):487–490.
  • 68. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75(1):46–52.
  • 69. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87(2):524–529.
  • 70. Sills ES, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligoovulatory women with clomiphene- resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol 2000;91(2):135–141.
  • 71. Zolghadri J, Tavana Z, Kazerooni T, Soveid M, Taghieh M. Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study. Fertil Steril 2008;90(3):727–730.
  • 72. Legro RS, Barnhart HX, Schlaff WD, et al; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356(6):551–566.
  • 73. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006;332(7556):1485.
  • 74. Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril 2005; 84(3):761–765.
  • 75. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48(12):1589–1595.
  • 76. Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19(6):1323–1330.
  • 77. Conway GS, Jacobs HS, Holly JM, Wass JA. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin- like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1990; 33(5):593–603.
  • 78. Liddell HS, Sowden K, Farquhar CM. Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome. Aust N Z J Obstet Gynaecol 1997;37(4):402–406.
  • 79. Rai R, Backos M, Rushworth F, Regan L. Polycystic ovaries and recurrent miscarriage-a reappraisal. Hum Reprod 2000; 15(3):612–615.
  • 80. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998;69(4):682–690.
  • 81. van Wely M, Bayram N, van der Veen F, Bossuyt PM. Predicting ongoing pregnancy following ovulation induction with recombinant FSH in women with polycystic ovary syndrome. Hum Reprod 2005;20(7):1827–1832.
  • 82. Metwally M, Ong KJ, Ledger WL, Li TC. Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence. Fertil Steril 2008;90(3):714–726.
  • 83. Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod 2004;19(7):1644–1646.
  • 84. Al-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Arch Gynecol Obstet 2004;270(4):205–210.
  • 85. Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol 1992;99(2):128–131.
  • 86. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10(10):2705– 2712.
APA BAŞTU E, MUTLU M, DURAL Ö, Buyru F (2012). Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. , 179 - 185.
Chicago BAŞTU Ercan,MUTLU Mehmet Fırat,DURAL Özlem,Buyru Faruk Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. (2012): 179 - 185.
MLA BAŞTU Ercan,MUTLU Mehmet Fırat,DURAL Özlem,Buyru Faruk Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. , 2012, ss.179 - 185.
AMA BAŞTU E,MUTLU M,DURAL Ö,Buyru F Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. . 2012; 179 - 185.
Vancouver BAŞTU E,MUTLU M,DURAL Ö,Buyru F Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. . 2012; 179 - 185.
IEEE BAŞTU E,MUTLU M,DURAL Ö,Buyru F "Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü." , ss.179 - 185, 2012.
ISNAD BAŞTU, Ercan vd. "Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü". (2012), 179-185.
APA BAŞTU E, MUTLU M, DURAL Ö, Buyru F (2012). Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. Endokrinolojide Diyalog Dergisi, 9(4), 179 - 185.
Chicago BAŞTU Ercan,MUTLU Mehmet Fırat,DURAL Özlem,Buyru Faruk Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. Endokrinolojide Diyalog Dergisi 9, no.4 (2012): 179 - 185.
MLA BAŞTU Ercan,MUTLU Mehmet Fırat,DURAL Özlem,Buyru Faruk Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. Endokrinolojide Diyalog Dergisi, vol.9, no.4, 2012, ss.179 - 185.
AMA BAŞTU E,MUTLU M,DURAL Ö,Buyru F Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. Endokrinolojide Diyalog Dergisi. 2012; 9(4): 179 - 185.
Vancouver BAŞTU E,MUTLU M,DURAL Ö,Buyru F Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü. Endokrinolojide Diyalog Dergisi. 2012; 9(4): 179 - 185.
IEEE BAŞTU E,MUTLU M,DURAL Ö,Buyru F "Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü." Endokrinolojide Diyalog Dergisi, 9, ss.179 - 185, 2012.
ISNAD BAŞTU, Ercan vd. "Tekrarlayan erken gebelik kayıplarında endokrinolojik hastalıkların rolü". Endokrinolojide Diyalog Dergisi 9/4 (2012), 179-185.
Sayfa Oluşturulma Tarihi
22-04-2024 18:57

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları